Haleon plc (HLN)vsIndivior PLC Ordinary Shares (INDV)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
INDV
Indivior PLC Ordinary Shares
$30.26
+5.11%
HEALTHCARE · Cap: $3.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 790% more annual revenue ($11.03B vs $1.24B). INDV leads profitability with a 17.0% profit margin vs 15.1%. INDV trades at a lower P/E of 17.9x. INDV earns a higher WallStSmart Score of 62/100 (C+).
HLN
Buy58
out of 100
Grade: C
INDV
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Margin of Safety
+55.6%
Fair Value
$76.75
Current Price
$30.26
$46.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Strong operational efficiency at 37.1%
Attractively priced relative to earnings
19.7% revenue growth
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
3.8% earnings growth
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : INDV
The strongest argument for INDV centers on Operating Margin, P/E Ratio, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 37.1%. Revenue growth of 19.7% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : INDV
The primary concerns for INDV are EPS Growth, Free Cash Flow.
Key Dynamics to Monitor
HLN profiles as a value stock while INDV is a growth play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.19 — expect wider price swings.
INDV is growing revenue faster at 19.7% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
INDV scores higher overall (62/100 vs 58/100), backed by strong 17.0% margins and 19.7% revenue growth. HLN offers better value entry with a 51.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?